• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Thank you government!

Nov. 25, 2014
By Mark McCarty
November is not always a spicy month where federal agencies are concerned, but FDA and CMS have come through to give us something to talk about. Below are a couple of items to mull over as you enjoy a leisurely, stress-free drive or comfy, un-cramped flight to celebrate Thanksgiving with loved ones. CMS makes a virtue of necessity The final guidance for the Medicare coverage with evidence development (CED) program is a relatively brief document considering the impact it will have, but also considering the length...
Read More

Elections and other events

Nov. 12, 2014
By Mark McCarty
There’s rarely a lack of activity on the policy and regulatory fronts in the world of med tech, and the past couple of weeks are no exception. Let’s talk about a few of those developments. Consequences or tea leaves? President Obama said in 2009 that elections have consequences, and that’s certainly true. But that’s a very different proposition than declining to “read the tea leaves on election results,” isn’t it Mr. President? (And then there’s MIT’s Jonathan Gruber extolling the virtues of a lack of transparency, not...
Read More

Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

Nov. 6, 2014
By Omar Ford
So what were the major talking points coming out of Cleveland Clinic's Medical Innovation Summit? It certainly wasn't a discussion on the lack of venture capital dollars available for med-tech start-ups - a topic that used to dominate conversations a few years back. Nor was it about the Affordable Care Act. No, the major talk at this year's Medical Innovation Summit, which was held last week, revolved around companion diagnostics. Look for new and exciting pharmaceuticals to be married to diagnostic tests for the foreseeable future. It seems in nearly every other panel something about combination diagnostics was mentioned. One...
Read More

The new Wild West: the life sciences

Oct. 30, 2014
By Mark McCarty
The life sciences have fostered an environment that can get pretty crazy, but let's face it: That's one of the things we like about the life sciences. Below are two stories that rival the tallest tales told of the Old West, but these two stories happen to be true stories. Hamburg; clinical trials for Ebola The latest outbreak of Ebola has generated a few rhetorical whoppers by elected and appointed officials. One of the weirder among them is a remark by FDA Commissioner Margaret Hamburg, who said in...
Read More

Say it with me... Google Glass is the next big thing in healthcare

Oct. 23, 2014
By Omar Ford
Physicians and surgeons are going to flock to Google Glass. That's my bold prediction and I'm sticking to it. I mean come on, just look at the impact the i-Pad has had on healthcare facilities across the country - sorry world. Now one of the main reasons Google Glass is going to make a strong impact, is because of it gives surgeons access to patient information and apps, at the benefit of freeing up the physician's hands. It's a common sense selling point, that I missed when I demo-ed the technology about a year ago. But what brought this fact...
Read More

Watching the Watchman and watching FDA

Oct. 17, 2014
By Mark McCarty
There is certainly no shortage of stories (or controversy) in the world of med tech, and here are a couple of stories that kept a lot of people glued to their computer screens (more or less) recently. FDA watches the Watchman FDA has heard a third affirmative vote from an advisory committee on the question of the Watchman left atrial appendage closure device, although the vote in favor of the device was close for the second consecutive time. It’s an interesting predicament for the agency because members of...
Read More

What we did and did not learn at AdvaMed 2014

Oct. 10, 2014
By Mark McCarty
The annual meeting of the Advanced Medical Technology Association, or AdvaMed, doesn’t include a lot of mind-blowing news, but there are often developments worthy of note. Following are a trio of stories addressing what was (not) said, and a few things to watch for over the next year or so. Physician payment sunburn? As reported by Medical Device Daily executive editor Holland Johnson in the Oct. 8 edition of MDD, Covidien’s chief medical officer Michael Tarnoff had a few interesting observations about sustainability. Tarnoff said docs are accustomed to getting what...
Read More

FDA, Menaflex, and the FDASIA escape hatch

Oct. 2, 2014
By Mark McCarty
As is widely known by now, FDA lost the second round of the legal struggle over the Menaflex 510(k), but the decision at the Court of Appeals for the District of Columbia sends the application back to FDA, where the device awaits an uncertain fate. Will FDA appeal to a higher court? I doubt it. The Menaflex story is one of the more convoluted med tech stories of the recent past. The first sponsor of the product, the now-shuttered ReGen Biologics, initially filed it as...
Read More

Med tech in the Land of Oz

Sep. 24, 2014
By Mark McCarty
Sometimes when I think about policy and regulatory matters in the world of med tech, I feel like I’m no longer in Kansas. Here are three stories of interest to device makers that might make one wonder who’s behind the curtain, and an icon of sorts for each. Jobs legislation; the Cowardly Lion The U.S. House of Representatives has passed H.R. 4, a bill that deals principally with jobs, but carries with it a repeal of the 2.3% medical device tax. So why is this bill a...
Read More

Strikeout: Three stories that missed

Sep. 4, 2014
By Mark McCarty
Baseball analogies are definitely overused, and now it’s my turn to abuse the privilege. Following are three stories in which somebody failed to reach base. Definition of a device One of the more interesting developments of late is the recall of a huge number of convenience kits assembled by Customed of Puerto Rico. FDA recently announced a recall of more than 200 of these so-called “devices,” but there’s something a little misleading about characterizing this as a medical device recall. So a convenience kit...
Read More
Previous 1 2 … 21 22 23 24 25 26 27 28 29 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe